Open access
Open access
Powered by Google Translator Translator

Pharmacology/Pharmaceutical Industry

[Preprint] Large cohort study in Brazil showed AstraZeneca vaccine had high overall effectiveness against severe disease to individuals up to 89 years of age. In comparison, CoronaVac had high overall effectiveness against severe disease in individuals up to 79 years.

7 Sep, 2021 | 10:54h | UTC

Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines – medRxiv

 

CDC report: Hospitalization rates for Covid-19 were 10 times higher among unvaccinated than among fully vaccinated adolescents.

7 Sep, 2021 | 10:52h | UTC

Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021 – CDC Morbidity and Mortality Weekly Report

Commentaries:

More kids hospitalized with Covid-19 in states with lower vaccination rates, CDC report finds – CNN

The hospitalization rate among teens who are unvaccinated is 10 times higher than teens who are vaccinated, new CDC data shows – Insider

Child COVID hospital cases up in low-vaccination states – CIDRAP

 

Commentary on Twitter

 

[Not published yet] Sinovac booster shot reverses drop in antibody activities against Delta-study.

7 Sep, 2021 | 10:47h | UTC

Sinovac booster shot reverses drop in antibody activities against Delta-study – Reuters

 

Commentary on Twitter

 

RCT: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels.

6 Sep, 2021 | 11:11h | UTC

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial – Nature Medicine

 

Commentary on Twitter

 

Large surveillance study finds severe adverse events after COVID-19 mRNA vaccination are rare.

6 Sep, 2021 | 11:02h | UTC

Surveillance for Adverse Events After COVID-19 mRNA Vaccination – JAMA

Editorial: Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink – JAMA

Commentaries:

mRNA COVID vaccines not tied to serious side effects – CIDRAP

Researchers find no serious health effects linked to mRNA COVID-19 vaccines – News Medical

 

Commentary on Twitter

 

M-A: Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia.

6 Sep, 2021 | 10:40h | UTC

Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link to abstract – $ for full-text)

Commentary: Long-acting injectable antipsychotics: more effective than oral medications at preventing hospitalisation and relapse in schizophrenia according to new review – The Mental Elf

 

Commentary on Twitter

https://twitter.com/TheLancetPsych/status/1382314592609693703

 

M-A: Effect of monthly injections of naltrexone on alcohol consumption.

6 Sep, 2021 | 10:39h | UTC

Effect of extended-release naltrexone on alcohol consumption: a systematic review and meta-analysis – Addiction (link to abstract – $ for full-text)

 

EU agency says to focus on vaccines first not booster shots.

3 Sep, 2021 | 10:34h | UTC

EU agency says to focus on vaccines first not booster shots – Associated Press

See also: European officials say COVID-19 booster isn’t urgent – CIDRAP

 

Reimagining construction and renovation of health care facilities during emergence from a pandemic.

3 Sep, 2021 | 10:19h | UTC

Reimagining Construction and Renovation of Health Care Facilities During Emergence from a Pandemic – Infectious Disease Clinics of North America

 

RCT: In patients with Immune Thrombocytopenia, the addition of Mycophenolate Mofetil to a standard glucocorticoid regimen reduced refractory or relapsed disease but was associated with decreased quality of life outcomes regarding physical function and fatigue.

3 Sep, 2021 | 10:15h | UTC

Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia – New England Journal of Medicine

 

RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.

2 Sep, 2021 | 10:17h | UTC

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial – The Lancet Respiratory Medicine

Commentaries:

Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial – The Lancet Respiratory Medicine

Rheumatoid Arthritis Drug Combined with Standard of Care May Help Reduce Mortality for Hospitalized COVID-19 Patients – Vanderbilt University Medical Center

 

Commentaries on Twitter

(thread – click for more)

 

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

2 Sep, 2021 | 10:05h | UTC

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar – medRxiv

Related:

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.

 

Commentary on Twitter (thread – click for more)

 

RCT: Ketamine administration in patients with acute painful sickle cell crisis was effective for pain control and reduced the cumulative morphine dose in the emergency department.

2 Sep, 2021 | 08:11h | UTC

Ketamine Administration for Acute Painful Sickle Cell Crisis: A Randomized Controlled Trial – Academic Emergency Medicine (link to abstract – $ for full-text)

 

[Preprint] Pfizer vaccine booster dose protection: A nationwide study from Israel – “Twelve days or more after the booster dose we found an 11.4-fold decrease in the relative risk of confirmed infection, and a >10-fold decrease in the relative risk of severe illness”.

1 Sep, 2021 | 09:59h | UTC

BNT162b2 vaccine booster dose protection: A nationwide study from Israel – medRxiv

 

Perspective | COVID-19 boosters in rich nations will delay vaccines for all.

1 Sep, 2021 | 09:56h | UTC

COVID-19 boosters in rich nations will delay vaccines for all – Nature

 

Commentaries on Twitter

 

Why is a third COVID-19 vaccine dose important for people who are immunocompromised?

1 Sep, 2021 | 09:57h | UTC

Why is a third COVID-19 vaccine dose important for people who are immunocompromised? – The Conversation

Related:

FDA authorizes additional Covid-19 vaccine dose for certain immunocompromised individuals – Other fully vaccinated individuals do not need an additional vaccine dose right now.

RCT: third dose of Moderna mRNA vaccine increases immunity in transplant recipients.

Study: Among kidney transplant recipients who did not respond after 2 doses, a third dose of an mRNA-1273 vaccine induced a serologic response in 49% of patients.

Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.

 

Study demonstrates a significantly higher humoral immunogenicity induced by the SARS-CoV-2 Moderna vaccine compared with the Pfizer- BioNTech vaccine.

31 Aug, 2021 | 09:04h | UTC

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273 – JAMA

Related:

Moderna may be superior to Pfizer against Delta variant — breakthrough odds rise with time.

[Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7% for Pfizer and 100.0% for Moderna.

 

Opinion | COVID vaccines: we need to find out which incentives actually work – the author argues that policies to promote vaccine uptake should be tested in randomized clinical trials.

31 Aug, 2021 | 08:56h | UTC

COVID vaccines: we need to find out which incentives actually work – The Conversation

 

#ESCCongress – RCT: Influenza vaccination early after a myocardial infarction (MI) or in high-risk coronary heart disease resulted in a lower risk of a composite of all-cause death, MI, or stent thrombosis compared with placebo.

31 Aug, 2021 | 08:52h | UTC

Influenza Vaccination after Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial – Circulation

Commentaries:

IAMI: Influenza Vaccine Beneficial for Post-MI Patients – TCTMD

Influenza Vaccination After Myocardial Infarction – IAMI – American College of Cardiology

Flu vaccine after heart attack reduces risk of death – Cardiovascular Business

 

Commentary on Twitter

 

#ESCCongress – RCT: In older patients with hypertension, intensive treatment with a SBP target of 110 to less than 130 mm Hg resulted in a lower incidence of cardiovascular events than standard treatment with a target of 130 to less than 150 mm Hg.

31 Aug, 2021 | 08:49h | UTC

Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

STEP: Aggressive BP Management in Older Chinese Patients With HTN Improved CV Outcomes vs. Standard Care – American College of Cardiology

STrategy of blood pressure intervention in the Elderly hypertensive Patients – STEP – American College of Cardiology

 

Commentary on Twitter

 

#ESCCongress – M-A: Polypills with and without aspirin substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death in primary cardiovascular disease prevention.

31 Aug, 2021 | 08:47h | UTC

Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis – The Lancet (link to abstract – $ for full-text)

Commentary: Combo therapy cuts risk of heart attacks and strokes in half – McMaster University

Related:

Opinion: A new important study supports wider use of the polypill

#AHA20 – Randomized trial: A polypill comprising statins, multiple blood pressure lowering drugs, and aspirin prevents cardiovascular events among patients at intermediate cardiovascular risk

Perspective: Are Polypills and Population-based Treatment the Next Big Things?

The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era

Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population

Randomized Trial: Effectiveness of Polypill for Primary and Secondary Prevention of Cardiovascular Diseases

Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology – Global Heart

Perspective: The Polypill and the Long Journey to Major Impact

Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care

 

Opinion | 10 Images That Illustrate The Shameful Global Vaccine Inequity – “This series of 10 images tell the story behind the great vaccine apartheid – the single biggest moral and scientific failure during this global crisis”.

29 Aug, 2021 | 18:53h | UTC

10 Images That Illustrate The Shameful Global Vaccine Inequity – by Madhukar Pai

 

Commentary on Twitter

 

New CDC Guidance says influenza and Covid vaccines can be given together – “COVID-19 vaccines and other vaccines may now be administered without regard to timing”

29 Aug, 2021 | 18:51h | UTC

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season – Centers for Disease Control and Prevention

Related: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States – Centers for Disease Control and Prevention

Commentary: Flu shot and a COVID jab? New 2021-2022 flu vaccine guidance points to both – McKnight’s

 

#ESCCongress – 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – SGLT2 inhibitors are now recommended for patients with heart failure with reduced ejection fraction regardless of the presence of diabetes.

29 Aug, 2021 | 18:25h | UTC

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC – European Heart Journal

News release: ESC Guidelines on heart failure management launched today – European Society of Cardiology

 

Commentary on Twitter

 

#ESCCongress – RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

29 Aug, 2021 | 18:19h | UTC

Empagliflozin in Heart Failure with a Preserved Ejection Fraction – New England Journal of Medicine

News release: Trial reports first successful results for heart failure with preserved ejection fraction – European Society of Cardiology

Commentary: Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction – EMPEROR-Preserved – American College of Cardiology

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.